申请人:Pfizer Inc.
公开号:US04503040A1
公开(公告)日:1985-03-05
Beta-lactamase inhibitors which are aminoacid esters of 6-alpha- and 6-beta-(hydroxymethyl)pencillanic acid 1,1-dioxides; pharmaceutically-acceptable salts thereof; conventional esters thereof which are hydrolyzable in vivo; bis-methanediol esters thereof; or mixed methanediol esters with said beta-lactamase inhibitors and sulbactam. Pharmaceutical compositions comprising said beta-lactamase inhibitors and a conventional beta-lactam antibiotic, said compositions useful in the treatment of bacterial infections. Compounds useful as intermediates in the synthesis of said beta-lactamase inhibitors. Antibacterial mixed bis-methanediol esters of said aminoacyloxymethyl penicillanic acid 1,1-dioxides and ampicillin or amoxicillin, also useful in the treatment of bacterial infections; and intermediates therefor.
β-内酰胺酶抑制剂,为6-α和6-β-(羟甲基)青霉烷酸1,1-二氧化物的氨基酸酯;其药用可接受的盐;体内可水解的常规酯;其双甲醇酯;或与该β-内酰胺酶抑制剂和舒巴坦混合的混合甲二醇酯。制药组合物包括该β-内酰胺酶抑制剂和常规β-内酰胺类抗生素,该组合物用于治疗细菌感染。化合物可用作合成该β-内酰胺酶抑制剂的中间体。抗菌的混合双甲醇酯为该氨基酰氧甲基青霉烷酸1,1-二氧化物和氨苄西林或阿莫西林,也可用于治疗细菌感染;以及其中间体。